Literature DB >> 11773372

Viral dynamics during structured treatment interruptions of chronic human immunodeficiency virus type 1 infection.

Simon D W Frost1, Javier Martinez-Picado, Lidia Ruiz, Bonaventura Clotet, Andrew J Leigh Brown.   

Abstract

Although antiviral agents which block human immunodeficiency virus (HIV) replication can result in long-term suppression of viral loads to undetectable levels in plasma, long-term therapy fails to eradicate virus, which generally rebounds after a single treatment interruption. Multiple structured treatment interruptions (STIs) have been suggested as a possible strategy that may boost HIV-specific immune responses and control viral replication. We analyze viral dynamics during four consecutive STI cycles in 12 chronically infected patients with a history (>2 years) of viral suppression under highly active antiretroviral therapy. We fitted a simple model of viral rebound to the viral load data from each patient by using a novel statistical approach that allows us to overcome problems of estimating viral dynamics parameters when there are many viral load measurements below the limit of detection. There is an approximate halving of the average viral growth rate between the first and fourth STI cycles, yet the average time between treatment interruption and detection of viral loads in the plasma is approximately the same in the first and fourth interruptions. We hypothesize that reseeding of viral reservoirs during treatment interruptions can account for this discrepancy, although factors such as stochastic effects and the strength of HIV-specific immune responses may also affect the time to viral rebound. We also demonstrate spontaneous drops in viral load in later STIs, which reflect fluctuations in the rates of viral production and/or clearance that may be caused by a complex interaction between virus and target cells and/or immune responses.

Entities:  

Mesh:

Year:  2002        PMID: 11773372      PMCID: PMC135793          DOI: 10.1128/jvi.76.3.968-979.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Fluctuations in HIV-1 viral load are correlated to CD4+ T-lymphocyte count during the natural course of infection.

Authors:  J Masel; R A Arnaout; T R O'Brien; J J Goedert; A L Lloyd
Journal:  J Acquir Immune Defic Syndr       Date:  2000-04-15       Impact factor: 3.731

2.  Significance testing of clinical data using virus dynamics models with a Markov chain Monte Carlo method: application to emergence of lamivudine-resistant hepatitis B virus.

Authors:  N J Burroughs; D Pillay; D Mutimer
Journal:  Proc Biol Sci       Date:  1999-12-07       Impact factor: 5.349

3.  Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy.

Authors:  T W Chun; R T Davey; M Ostrowski; J Shawn Justement; D Engel; J I Mullins; A S Fauci
Journal:  Nat Med       Date:  2000-07       Impact factor: 53.440

4.  Immune control of HIV-1 after early treatment of acute infection.

Authors:  E S Rosenberg; M Altfeld; S H Poon; M N Phillips; B M Wilkes; R L Eldridge; G K Robbins; R T D'Aquila; P J Goulder; B D Walker
Journal:  Nature       Date:  2000-09-28       Impact factor: 49.962

5.  Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression.

Authors:  L Ruiz; J Martinez-Picado; J Romeu; R Paredes; M K Zayat; S Marfil; E Negredo; G Sirera; C Tural; B Clotet
Journal:  AIDS       Date:  2000-03-10       Impact factor: 4.177

6.  Dynamics of HIV-specific CD8+ T lymphocytes with changes in viral load.The RESTIM and COMET Study Groups.

Authors:  L Mollet; T S Li; A Samri; C Tournay; R Tubiana; V Calvez; P Debré; C Katlama; B Autran
Journal:  J Immunol       Date:  2000-08-01       Impact factor: 5.422

7.  Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption.

Authors:  E Papasavvas; G M Ortiz; R Gross; J Sun; E C Moore; J J Heymann; M Moonis; J K Sandberg; L A Drohan; B Gallagher; J Shull; D F Nixon; J R Kostman; L J Montaner
Journal:  J Infect Dis       Date:  2000-08-17       Impact factor: 5.226

8.  Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy.

Authors:  P A Haslett; D F Nixon; Z Shen; M Larsson; W I Cox; R Manandhar; S M Donahoe; G Kaplan
Journal:  J Infect Dis       Date:  2000-04-05       Impact factor: 5.226

9.  Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy.

Authors:  L Zhang; C Chung; B S Hu; T He; Y Guo; A J Kim; E Skulsky; X Jin; A Hurley; B Ramratnam; M Markowitz; D D Ho
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

10.  Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy.

Authors:  H F Günthard; S D Frost; A J Leigh-Brown; C C Ignacio; K Kee; A S Perelson; C A Spina; D V Havlir; M Hezareh; D J Looney; D D Richman; J K Wong
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

View more
  21 in total

1.  Costs versus benefits: best possible and best practical treatment regimens for HIV.

Authors:  O Krakovska; L M Wahl
Journal:  J Math Biol       Date:  2007-01-05       Impact factor: 2.259

2.  Viral evolution during structured treatment interruptions in chronically human immunodeficiency virus-infected individuals.

Authors:  Javier Martinez-Picado; Simon D W Frost; Nuria Izquierdo; K Morales-Lopetegi; Silvia Marfil; Teresa Puig; Cecilia Cabrera; Bonaventura Clotet; Lidia Ruiz
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

3.  Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases.

Authors:  Timothy J Henrich; Emily Hanhauser; Francisco M Marty; Michael N Sirignano; Sheila Keating; Tzong-Hae Lee; Yvonne P Robles; Benjamin T Davis; Jonathan Z Li; Andrea Heisey; Alison L Hill; Michael P Busch; Philippe Armand; Robert J Soiffer; Marcus Altfeld; Daniel R Kuritzkes
Journal:  Ann Intern Med       Date:  2014-09-02       Impact factor: 25.391

4.  Human immunodeficiency virus-specific CD8(+) T-cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy.

Authors:  Annette Oxenius; Angela R McLean; Marek Fischer; David A Price; Sarah J Dawson; Roland Hafner; Christine Schneider; Helen Joller; Bernard Hirschel; Rodney E Phillips; Rainer Weber; Huldrych F Günthard
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

5.  Boosting immunity by antiviral drug therapy: a simple relationship among timing, efficacy, and success.

Authors:  Natalia L Komarova; Eleanor Barnes; Paul Klenerman; Dominik Wodarz
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-06       Impact factor: 11.205

6.  Lack of longitudinal intrapatient correlation between p24 antigenemia and levels of human immunodeficiency virus (HIV) type 1 RNA in patients with chronic hiv infection during structured treatment interruptions.

Authors:  Julia G Prado; Ayumi Shintani; Margarita Bofill; Bonaventura Clotet; Lidia Ruiz; Javier Martinez-Picado
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

7.  A case of multiorgan failure following interruption of antiretroviral treatment.

Authors:  M Crespo; J C Paradiñeiro; E Ribera; I Ruiz; V Falcó; J Lopez-Quiñones; I Ocaña; A Pahissa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-12-11       Impact factor: 3.267

8.  A randomized, controlled, trial of short cycle intermittent compared to continuous antiretroviral therapy for the treatment of HIV infection in Uganda.

Authors:  Steven J Reynolds; Cissy Kityo; Claire W Hallahan; Geoffrey Kabuye; Diana Atwiine; Frank Mbamanya; Francis Ssali; Robin Dewar; Marybeth Daucher; Richard T Davey; Peter Mugyenyi; Anthony S Fauci; Thomas C Quinn; Mark R Dybul
Journal:  PLoS One       Date:  2010-04-22       Impact factor: 3.240

9.  Structured treatment interruptions (STIs) in HIV-1 infected pediatric populations increases interferon gamma production and reduces viremia.

Authors:  William Borkowsky; Ram Yogev; Petronella Muresan; Elizabeth McFarland; Lisa Frenkel; Terry Fenton; Edmond Capparelli; Jack Moye; Paul Harding; Nina Ellis; Barbara Heckman; Joyce Kraimer
Journal:  Vaccine       Date:  2008-01-04       Impact factor: 3.641

10.  Positive feedback through inflammation creates bistable behavior in HIV tissue sanctuaries.

Authors:  Aditya Jagarapu; Rajveer Mann; Michael J Piovoso; Ryan Zurakowski
Journal:  Proc Am Control Conf       Date:  2019-08-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.